Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis
Tóm tắt
Từ khóa
Tài liệu tham khảo
del Rincon, 2001, High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors, Arthritis Rheum, 44, 2737, 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#
Wallberg-Jonsson, 2004, Which factors are related to the presence of atherosclerosis in rheumatoid arthritis?, Scand J Rheumatol, 33, 373, 10.1080/03009740410010308
Sattar, 2003, Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis, Circulation, 108, 2957, 10.1161/01.CIR.0000099844.31524.05
Bisoendial, 2010, The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events, Semin Thromb Hemost, 36, 452, 10.1055/s-0030-1254054
Ristic, 2010, Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment, Rheumatology (Oxford), 49, 1076, 10.1093/rheumatology/kep456
Navarro-Millan, 2012, Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor, Clin Ther, 34, 788, 10.1016/j.clinthera.2012.02.014
Kawashiri, 2011, Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis, Rheumatol Int, 31, 451, 10.1007/s00296-009-1303-y
Maini, 2006, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum, 54, 2817, 10.1002/art.22033
Nishimoto, 2004, Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial, Arthritis Rheum, 50, 1761, 10.1002/art.20303
Nishimoto, 2007, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab, Ann Rheum Dis, 66, 1162, 10.1136/ard.2006.068064
Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, Lancet, 371, 987, 10.1016/S0140-6736(08)60453-5
Jones, 2010, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Ann Rheum Dis, 69, 88, 10.1136/ard.2008.105197
EMEA, 2010
Nishimoto, 2003, Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study, J Rheumatol, 30, 1426
Garcia-Gomez, 2009, Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis, J Rheumatol, 36, 1365, 10.3899/jrheum.080928
Gierens, 2000, Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements, Arterioscler Thromb Vasc Biol, 20, 1777, 10.1161/01.ATV.20.7.1777
Dougados, 2012, Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY), Ann Rheum Dis
Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107
Nierman, 2005, Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance, Metabolism, 54, 1499, 10.1016/j.metabol.2005.05.016
Levels, 2003, Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure, Crit Care Med, 31, 1647, 10.1097/01.CCM.0000063260.07222.76
Kempen, 1988, Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans, J Lipid Res, 29, 1149, 10.1016/S0022-2275(20)38456-X
Kesaniemi, 1987, Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population, Eur J Clin Invest, 17, 391, 10.1111/j.1365-2362.1987.tb01132.x
Kappelle, 2012, Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL, Eur J Clin Invest, 42, 487, 10.1111/j.1365-2362.2011.02604.x
Taskinen, 1990, Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM, Diabetes, 39, 1017, 10.2337/diab.39.9.1017
Nonogaki, 1995, Interleukin-6 stimulates hepatic triglyceride secretion in rats, Endocrinology, 136, 2143, 10.1210/endo.136.5.7720663
Cooper, 1997, Hepatic uptake of chylomicron remnants, J Lipid Res, 38, 2173, 10.1016/S0022-2275(20)34932-4
Dallinga-Thie, 2010, The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight, Atherosclerosis, 211, 1, 10.1016/j.atherosclerosis.2009.12.027
Masuda, 2011, Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia, J Atheroscler Thromb, 18, 1062, 10.5551/jat.10470
Smith, 1999, Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state, Eur J Clin Invest, 29, 204, 10.1046/j.1365-2362.1999.00431.x
Hingorani, 2012, The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis, Lancet, 379, 1214, 10.1016/S0140-6736(12)60110-X
Choy, 2009, Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions, Ann Rheum Dis, 68, 460, 10.1136/ard.2008.101964
Pollono, 2010, A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis, Clin Rheumatol, 29, 947, 10.1007/s10067-010-1405-7
Sniderman, 2000, Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm, Atherosclerosis, 148, 215, 10.1016/S0021-9150(99)00282-8
Havel, 1984, The formation of LDL: mechanisms and regulation, J Lipid Res, 25, 1570, 10.1016/S0022-2275(20)34434-5
Dursunoglu, 2005, Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation, Rheumatol Int, 25, 241, 10.1007/s00296-004-0438-0
Clotet, 2003, Impact of nevirapine on lipid metabolism, J Acquir Immune Defic Syndr, 34, S79, 10.1097/00126334-200309011-00012
Popa, 2005, Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis, Ann Rheum Dis, 64, 303, 10.1136/ard.2004.023119
Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4
Ridker, 2005, Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women, JAMA, 294, 326, 10.1001/jama.294.3.326
Sarwar, 2012, Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies, Lancet, 379, 1205, 10.1016/S0140-6736(11)61931-4
Micha, 2011, Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease, Am J Cardiol, 108, 1362, 10.1016/j.amjcard.2011.06.054
Westlake, 2011, Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review, Rheumatology (Oxford), 50, 518, 10.1093/rheumatology/keq316